Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic
- PMID: 36163166
- PMCID: PMC9477965
- DOI: 10.1016/j.jcf.2022.09.006
Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic
Abstract
Background: The onset of the COVID-19 pandemic was associated with restricted community movement and limited access to healthcare facilities, resulting in changed clinical service delivery to people with cystic fibrosis (CF). This study aimed to determine clinical outcomes of Australian adults and children with CF in the 12-months following the onset of the COVID-19 pandemic.
Methods: This longitudinal cohort study used national registry data. Primary outcomes were 12-month change in percent predicted forced expiratory volume in one second (FEV1 %pred), body mass index (BMI) in adults and BMI z-scores in children. A piecewise linear mixed-effects model was used to determine trends in outcomes before and after pandemic onset.
Results: Data were available for 3662 individuals (median age 19.6 years, range 0-82). When trends in outcomes before and after pandemic onset were compared; FEV1 %pred went from a mean annual decline of -0.13% (95%CI -0.36 to 0.11) to a mean improvement of 1.76% (95%CI 1.46-2.05). Annual trend in BMI improved from 0.03 kg/m2 (95%CI -0.02-0.08) to 0.30 kg/m2 (95%CI 0.25-0.45) and BMI z-scores improved from 0.05 (95%CI 0.03-0.07) to 0.12 (95%CI 0.09-0.14). Number of hospitalisations decreased from a total of 2656 to 1957 (p < 0.01). Virtual consultations increased from 8% to 47% and average number of consultations per patient increased from median (IQR) of 4(2-5) to 5(3-6) (p < 0.01).
Conclusion: In the 12-months following the onset of the COVID-19 pandemic, there was an improvement in the clinical outcomes of people with CF when compared to the pre-pandemic period.
Keywords: COVID-19; Cystic fibrosis; Telehealth.
Copyright © 2022. Published by Elsevier B.V.
References
-
- Ketchell RI. Telemedicine is the way forward for the management of cystic fibrosis–the case in favour. Paediatr Respir Rev. 2018;26:19–21. - PubMed
-
- Davies G, Rowbotham NJ, Smith S, Elliot ZC, Gathercole K, Rayner O, et al. Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials. J Cystic Fibrosis. 2020;19(3):499–502. - PubMed
-
- Lenney W. Telemedicine is the way forward for the management of cystic fibrosis–the case against. Paediatr Respir Rev. 2018;26:22–23. - PubMed
-
- Baxter J., Hayes A., Gray M. Australian Institute of Family Studies; 2011. Families in regional, rural and remote Australia (Fact Sheet) [press release]
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
